AAX’s CEO Maria L. Knudsen interviewed by Scrip
Our CEO Maria Lisa Knudsen sat down for an interview with Scrip to talk about AAX Biotech and our exciting technologies, summarized nicely in this article “Ambitious AAX Wants To Be Key Player In Next-Generation Antibodies”:
“Emerging Company Profile: The Swedish biotech’s CEO Maria Lisa Knudsen believes that the firm’s two technologies make it an attractive prospective partner for big pharma.
… AAX can boast not one but two technologies which both aim to produce more effective antibody-based medicines. The first is Opti-mAb which improves the stability and production of single- chain variable fragments (scFv), an antibody format used in CAR-T and bispecifics.
AAX's second technology is Seqitope, which the company says is an innovative method for antibody epitope mapping which yields high-resolution results while also being high throughput.”
